Prakt. lékáren. 2008; 4(1): 9-14

Ochrana očkováním proti virovým hepatitidám

RNDr. Marek Petráš
Specialista v oboru vakcinologie, Praha

Dnes běžně používané vakcíny proti virové hepatitidě typu A a typu B přispěly k prevenci těchto onemocnění. I tak tyto vakcíny mají své limity v účinnosti a imunogenitě, proto je vhodné individuálně posoudit spolehlivost těchto očkování.

Keywords: hepatitida, vakcína, účinnost

Published: March 15, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráš M. Ochrana očkováním proti virovým hepatitidám. Praktické lékárenství. 2008;4(1):9-14.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-1213. Go to original source... Go to PubMed...
    2. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87(Suppl 3A): 39-45. Go to original source... Go to PubMed...
    3. Aristegui J, Garrate E, Gonzales A et al. A new tetravalent vaccine containing diphteria and tetanus toxoids, whole-cell B. pertussis and a recombinant hepatitis B surface antigen administere at 2, 4 and 6 months of age. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); (Poster H137), Oct 4-7, Orlando, USA, 1994.
    4. Armstrong ME, Giesa PA, Davide JP et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA, from the live attenuated virus strain CR326F. J Hepatol 1993; 18(Suppl 2): S20-S26. Go to original source... Go to PubMed...
    5. Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995; 171(Suppl 1): S70-S72. Go to original source... Go to PubMed...
    6. Barbara Watson, David J. West, Andrew Chilkatowsky, Sharon Piercy, Virginia A. Ioli, Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine, Vaccine 19 (2001) 3164-3168. Go to original source... Go to PubMed...
    7. Bock HL, Kruppenbacher J, Sänger R et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996; 156: 2226-2231. Go to original source...
    8. Bruguera M, Cremades M, Salinas R et al. Impaired responmse to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14: 27-30. Go to original source... Go to PubMed...
    9. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(suppl 1): S44-S49. Go to original source... Go to PubMed...
    10. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA-genes are involved. Tissue Antigens.
    11. Emini EA, Eliis RW, Miller WJ et al. Production and immunologic analysis of recombinant hepatitis B vaccine. J Infect 1986; 13(suppl A): 3-9. Go to original source... Go to PubMed...
    12. Flehming B, Heinricy U, Pfisterer M. Prospects for a hepatitis A virus vaccine. Prog Med Virol 1990; 37: 56-71.
    13. Flehming B, Mauler RF, Noll G et al. Viral Hepatitis and Liver Disease. New York, Alan R Liss, 1988; pp.87-90.
    14. Flehming B, Vallbracht A, Wuster G. Hepatitis A in cell culture. 3. Propagation of hepatitis virus in human embryo cells and human embryo fibroblast strains. Med Microbiol Immunol 1981; 170: 83-89. Go to original source... Go to PubMed...
    15. Gluck R, Mischler R, Brantschen S et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J clin Invest 1992; 90: 2491-2495. Go to original source... Go to PubMed...
    16. Gust ID, Lehmann NI, Crowe S et al. The origin of the HM175 strain of hepatitis A virus. J Infect Dis 1985; 151: 365-367. Go to original source... Go to PubMed...
    17. Hadler SC, Judson FN, O'Malley PM et al. Studies of hepatitis B vaccine in homosexual men. In Coursaget P, Tong MJ (eds.), Progress in Hepatitis B Immunization. Paris, John Libby Eurotest. 1990; 165-175.
    18. Harries AD, Clark M, Beeching NJ et al. Early anti-HBs antibody response o accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect 1991; 23(3): 251-254. Go to original source... Go to PubMed...
    19. Heinricy U, Stierhof ZD, Pfisterer M, Flehming B. Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol 1987; 68: 2487-2493. Go to original source... Go to PubMed...
    20. Hess G, Hingst V, Cseke J et al. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol Infect Dis 1992; 11: 334-340. Go to original source... Go to PubMed...
    21. Horng YC, Chang MH, Lee CY, Safary A, Andre FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993; 12: 359-362. Go to original source... Go to PubMed...
    22. Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis.
    23. Chiaramonte M, Majori S, Ngatchu T et al. Two difference dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996; 14: 135-137. Go to original source... Go to PubMed...
    24. Iwarson S. New approaches to hepatitis A and B vaccines. APMIS 1995; 103: 321-326. Go to original source... Go to PubMed...
    25. Keet IPM, van-Doorum G, Safary A et al. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6: 509-510. Go to original source... Go to PubMed...
    26. Lau Y-L, Tam AYC, Ng KW et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121: 962-965. Go to original source... Go to PubMed...
    27. Laukamm-Josten U, von Laer G, Feldmeier H et al. Active immunization against hepatitis B: immunogenicity of a recombinantn DNA vaccine in females, heterosexual and homosexual males. Postgrad Med J 1987; 63(suppl 2): 143-146.
    28. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983; 148: 1033-1039. Go to original source... Go to PubMed...
    29. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204. Go to original source... Go to PubMed...
    30. Lemon SM. Hepatitis A virus: Current concepts of the molecular virology, immunology and approaches to vaccine development. Rev Med Virol 1992; 2: 73-87. Go to original source...
    31. Nalin DR, Kuter BJ, Brown L et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adults populations: an overview. J Hepatol 1993; 18(suppl 2): S51-S55. Go to original source... Go to PubMed...
    32. Palmovic D, Crnjakovic-Palmovic J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol 1994; 10: 541-547. Go to original source... Go to PubMed...
    33. Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 1992; 10 (suppl 1): S99-S101. Go to original source... Go to PubMed...
    34. Piazza M, Safary A, Vegnente A et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 1999; 17: 585-588. Go to original source... Go to PubMed...
    35. Pietro Dentico, Pietro Crovari, Piero Luigi Lai, Franca Ponzio, Assad Safary, Anna Pellegrino, Francois Meurice, Alberta Di Pasquale, Nadia Tornieporth, Anna Volpe, Giancarlo Icardi, Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term nonprotective antibody titres, Vaccine 20 (2002) 3725-3730. Go to original source... Go to PubMed...
    36. Poovorawan Y, Theamboonlers A, Sanpavat S et al. Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. Asian Pac J Allergy Immunol 1999; 17: 113-120. Go to PubMed...
    37. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979; 160: 213-221. Go to original source... Go to PubMed...
    38. Shapiro CN, Letson GW, Kuehn D et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants (Abstract H61). In: 1995 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: American Society for Microbiology, 1995; 190.
    39. Sitrin RD, Wampler DE, Ellis RW. Survey of licensed hepatitis B vaccines and their production processes. In Elis RW (ed). Hepatitis B Vaccines in Clincial Practices. New Yourk, Marcel Dekker 1993; pp. 83-101.
    40. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8(suppl): S69-S73. Go to original source... Go to PubMed...
    41. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841. Go to original source... Go to PubMed...
    42. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44: 446-451. Go to original source... Go to PubMed...
    43. Van Herck K, Van Damme P, Thoelen S. A high potency inactivated hepatitis A vaccine: long term follow-up (Abstract A02). final program/book of abstracts. 6th Conference of the International Society of Travel Medicine. Stone Mountain, GA: International Society of Travel Medicine, 1999. Go to original source...
    44. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis 1997; 175: 674-677. Go to original source... Go to PubMed...
    45. Wainwright RB, McMahon BJ, Bulkow LR et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Askimo population. JAMA 1989; 261: 2362-2366. Go to original source...
    46. Wang LY, Lin HH, Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago, Vaccine. 2007; Aug 1. Go to original source... Go to PubMed...
    47. Watson B, West DJ, Chilkatowsky A, Piercy S, Loli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine; Vaccine 19(2001): 3164-3168. Go to original source... Go to PubMed...
    48. WHO VHPB Hepatitis B as an occupational hazard - European Occupational Health Series N'8 1994: 1-64.
    49. Wiedermann G, Kondi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Tropica 1998; 69: 121-125. Go to original source... Go to PubMed...
    50. Wiedermann G, Kundi M, Ambrosch F et al. Inactivated hepatitis A vaccine: Long term antibody persistence. Vaccine 1997; 15: 612-615. Go to original source... Go to PubMed...
    51. Wilkinson SE, Morath M, Bennett DL et al. Accelerated schedule of hepatitis B vaccination in high-risk youth. J Paediatr Child Health 1996; 32: 60-62. Go to original source... Go to PubMed...
    52. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of the clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13(Suppl A): 39-45. Go to original source... Go to PubMed...
    53. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384. Go to original source... Go to PubMed...
    54. Zuckerman JN, Van Damme P, Van Herck K, Löscher T. Vaccination options for lastminute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide; Travel Med Infect Dis 2003; 1: 219-226, 14. 5. 2004. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.